Abstract
Mice challenged with L5178Y lymphoma cells expression high levels of the glycolipid asialo GM2 (gangliotriosylceramide) were protected from tumor growth by passive administration of a monoclonal antibody specific for the glycolipid; in a few antibody-treated mice, ascites cells eventually proliferated which contained a reduced chemical quantity of the glycolipid antigen (3). We now report that the cells emerging from antibody-treated mice had abnormal marker chromosomes identical to those in the cells used for challenge, indicating that the emergent cells were progeny of the challenge inoculum. Flow cytometric analysis revealed that asialo GM2 was undetectable on the surface of greater than 95% of the tumor cells from antibody-treated mice, whereas surface display of H-2 determinants was unchanged from that of the cells used for challenge. Tumor cells arising in challenged but untreated mice consisted of a mixture of asialo GM2-positive and - negative cells, indicating the presence of selective pressures in these mice as well. None of the cells taken from tumor bearing mice differed significantly from the challenge cells in their susceptibility to natural killer cell attack, suggesting that resistance to natural killer cell lysis was not responsible for the proliferation of these cells in vivo. When cells derived from an antibody-treated mouse were used to challenge mice, serotherapy with anti-asialo GM2 had no effect on mouse survival. These results suggest that serotherapy may complement a host anti-tumor response, from which only asialo GM2 deficient cells can escape.
Full Text
The Full Text of this article is available as a PDF (855.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Celis E., Chang T. W., Eisen H. N. Cyclical changes in susceptibility of a myeloma tumor (LPC-1) to immune destruction. III. Periodic production of a cell surface glycoprotein and changes in reactivity with cytotoxic T cells and anti-H-2d sera. J Immunol. 1979 Jun;122(6):2245–2250. [PubMed] [Google Scholar]
- Durdik J. M., Beck B. N., Clark E. A., Henney C. S. Characterization of a lymphoma cell variant selectively resistant to natural killer cells. J Immunol. 1980 Aug;125(2):683–688. [PubMed] [Google Scholar]
- Kawase I., Urdal D. L., Brooks C. G., Henney C. S. Selective depletion of NK cell activity in vivo and its effect on the growth of NK-sensitive and NK-resistant tumor cell variants. Int J Cancer. 1982 May 15;29(5):567–574. doi: 10.1002/ijc.2910290513. [DOI] [PubMed] [Google Scholar]
- Kemshead J. T., Walsh F., Pritchard J., Greaves M. Monoclonal antibody to ganglioside GQ discriminates between haemopoietic cells and infiltrating neuroblastoma tumour cells in bone marrow. Int J Cancer. 1981;27(4):447–452. doi: 10.1002/ijc.2910270405. [DOI] [PubMed] [Google Scholar]
- Miller D. A., Firschein I. L., Dev V. G., Tantravahi R., Miller O. J. The gorilla karyotype: chromosome lengths and polymorphisms. Cytogenet Cell Genet. 1974;13(6):536–550. doi: 10.1159/000130305. [DOI] [PubMed] [Google Scholar]
- Miller R. A., Maloney D. G., Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982 Mar 4;306(9):517–522. doi: 10.1056/NEJM198203043060906. [DOI] [PubMed] [Google Scholar]
- Pukel C. S., Lloyd K. O., Travassos L. R., Dippold W. G., Oettgen H. F., Old L. J. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med. 1982 Apr 1;155(4):1133–1147. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinhold K. J., Goldstein L. T., Wheelock E. F. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J Exp Med. 1979 Mar 1;149(3):732–744. doi: 10.1084/jem.149.3.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinhold K. J., Miller D. A., Wheelock E. F. The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J Exp Med. 1979 Mar 1;149(3):745–757. doi: 10.1084/jem.149.3.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wiels J., Fellous M., Tursz T. Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6485–6488. doi: 10.1073/pnas.78.10.6485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Young W. W., Jr, Durdik J. M., Urdal D., Hakomori S., Henney C. S. Glycolipid expression in lymphoma cell variants: chemical quantity, immunologic reactivity, and correlations with susceptibility to NK cells. J Immunol. 1981 Jan;126(1):1–6. [PubMed] [Google Scholar]
- Young W. W., Jr, Hakomori S. I. Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo. Science. 1981 Jan 30;211(4481):487–489. doi: 10.1126/science.7455688. [DOI] [PubMed] [Google Scholar]
- Young W. W., Jr, MacDonald E. M., Nowinski R. C., Hakomori S. I. Production of monoclonal antibodies specific for two distinct steric portions of the glycolipid ganglio-N-triosylceramide (asialo GM2). J Exp Med. 1979 Oct 1;150(4):1008–1019. doi: 10.1084/jem.150.4.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]